1. Home
  2. TSLX vs TSHA Comparison

TSLX vs TSHA Comparison

Compare TSLX & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sixth Street Specialty Lending Inc.

TSLX

Sixth Street Specialty Lending Inc.

HOLD

Current Price

$19.23

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$4.55

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSLX
TSHA
Founded
2010
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.5B
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
TSLX
TSHA
Price
$19.23
$4.55
Analyst Decision
Buy
Strong Buy
Analyst Count
10
9
Target Price
$23.50
$10.56
AVG Volume (30 Days)
745.1K
2.5M
Earning Date
02-12-2026
02-27-2026
Dividend Yield
10.66%
N/A
EPS Growth
N/A
N/A
EPS
1.81
N/A
Revenue
$449,055,000.00
$6,310,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.62
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.58
$1.05
52 Week High
$25.17
$6.02

Technical Indicators

Market Signals
Indicator
TSLX
TSHA
Relative Strength Index (RSI) 25.63 45.07
Support Level $19.63 $4.37
Resistance Level $20.35 $4.70
Average True Range (ATR) 0.59 0.25
MACD -0.21 0.02
Stochastic Oscillator 3.85 35.24

Price Performance

Historical Comparison
TSLX
TSHA

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Share on Social Networks: